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Abstract—Microalbuminuria is a strong indicator of the risk of future cardiovascular disease and renal dysfunction.
Slightly increased levels of homocysteine, an independent risk factor for atherothrombotic disease, have recently been
found to be associated with the presence of (micro)albuminuria. However, it is unknown whether increased
homocysteine levels precede the occurrence of (micro)albuminuria. Normoalbuminuric subjects (n5316, 66 with
non–insulin-dependent diabetes mellitus [NIDDM]) of an age-stratified, sex-stratified, and glucose tolerance–stratified
sample of a population-based cohort study were investigated at baseline and after a mean follow-up duration of 6.1
years. Development of (micro)albuminuria was defined as a mean albumin-to-creatinine ratio .2.0 mg/mmol at the
follow-up examination. The cumulative incidence of (micro)albuminuria was 14.0% (9.7 % to 18.3%) among
nondiabetic subjects and 22.7% (12.9% to 32.5%) among NIDDM patients. Age-adjusted, sex-adjusted, and glucose
tolerance status–adjusted logistic regression analyses showed development of (micro)albuminuria to be significantly
associated with baseline homocysteine levels .19.0 mmol/L compared with homocysteine levels ,9.1 mmol/L (odds
ratio [OR] 5.1, 95% CI 1.1 to 23.0). For homocysteine levels of 9.1 to 14.0 mmol/L and 14.1 to 19.0 mmol/L, the values
were OR 1.2 (95% CI 0.5 to 3.0) and OR 1.8 (95% CI 0.6 to 5.3), respectively. Additional adjustment for baseline insulin
resistance, blood pressure, body mass index, presence of cardiovascular disease and retinopathy, current smoking, or
estimates of glomerular filtration rate did not materially affect the results. Substituting homocysteine levels as a
continuous variable for categories of homocysteine levels showed that a 5-mmol/L increase of the homocysteine level
was associated with an increased risk of developing (micro)albuminuria (OR 1.38, 95% CI 0.97 to 1.95) . Analyses
performed in nondiabetic and diabetic subjects separately gave similar results among nondiabetic subjects. Among
diabetic subjects, the association between homocysteine level and (micro)albuminuria could not be estimated, because
there was an insufficient number of diabetic subjects with high homocysteine levels. Hyperhomocysteinemia is an
independent determinant of the development of (micro)albuminuria among nondiabetic subjects, even after adjustment
for estimates of glomerular filtration rate. We could neither confirm nor reject an association between homocysteine
levels and the development of (micro)albuminuria among NIDDM subjects. These data suggest that homocysteine may
play a pathophysiological role in the development of (micro)albuminuria. (Arterioscler Thromb Vasc Biol. 2001;21:74-81.)
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Microalbuminuria, a slightly increased urinary albuminexcretion, is associated with an increased risk of
cardiovascular morbidity and mortality among patients with
non–insulin-dependent diabetes mellitus (NIDDM)1 and
among nondiabetic subjects.2 Furthermore, the presence of
microalbuminuria in diabetes identifies subjects at high risk
of developing persistent proteinuria.1,3 Thus, microalbumin-
uria is a strong indicator of the risk of future cardiovascular
disease and renal dysfunction. Therefore, elucidating the
determinants of microalbuminuria is of great importance and
may lead to knowledge about the pathophysiological mech-
anisms necessary for therapeutic innovations.
Prospective observational studies, conducted mainly among
diabetic subjects, have identified several determinants associated
with the development of microalbuminuria, ie, age, male sex,
blood pressure, poor glycemic control, smoking, retinopathy,
and coronary heart disease.4–11 Other determinants, such as
insulin resistance (and related variables12–14) and increased
protein intake,15,16 have been proposed on the basis of their
cross-sectional associations with microalbuminuria.
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Interestingly, slightly increased levels of homocysteine, a
sulfur-containing amino acid formed by demethylation of
methionine, have recently been found to be associated with
the presence of microalbuminuria,16–18 although not all stud-
ies concur.19 By definition, however, these cross-sectional
investigations16–19 cannot establish whether increased homo-
cysteine levels precede the occurrence of microalbuminuria,
which would be an important step toward establishing in-
creased homocysteine levels as a causal determinant of
microalbuminuria.
Therefore, we performed a prospective study in an age-
stratified, sex-stratified, and glucose tolerance–stratified sam-
ple of a population-based cohort study to investigate the
association between homocysteine levels and the develop-
ment of (micro)albuminuria. In addition, we gave particular
attention to other proposed determinants for developing
(micro)albuminuria, namely, high blood pressure, poor gly-
cemic control, obesity, insulin resistance, a high protein
intake, retinopathy, and cardiovascular disease.4–16,20
Methods
General Study Design
The Hoorn Study is a cohort study of disturbances of glucose
tolerance and cardiovascular disease in a general white population
aged 50 to 75 years (n52484). The baseline examinations were
conducted from October 1989 until February 1992.21,22 For reasons
of efficiency, we chose to study a smaller (n5631), but still
randomly selected, sample in more detail with regard to cardiovas-
cular disease. This sample was stratified for age, sex, and glucose
tolerance status. We oversampled subjects with impaired glucose
tolerance and NIDDM to increase the power of comparisons with
subjects with normal glucose tolerance. Approximately 6 years after
the baseline examination, from January 1996 until December 1997,
all subjects were invited for a follow-up examination.
For the present analyses, we focused only on those subjects who,
at baseline, were normoalbuminuric and did not use ACE inhibitors
(n5509, 252 subjects with normal glucose tolerance, 136 subjects
with impaired glucose tolerance, and 121 subjects with NIDDM).
Between the baseline and the follow-up examinations, 50 (9.8%)
subjects died, 32 (6.3%) moved out of Hoorn and were therefore not
invited, and 87 (17.1%) did not respond to the invitation, leaving 340
subjects participating in the follow-up examination (Figure 1).
All participants gave informed consent for the baseline and
follow-up examinations, which were approved by the local ethics
committee.
Procedures at the Baseline Examination
An early morning first-voided spot urine sample was obtained, and
the urinary albumin-to-creatinine ratio was determined. In a repre-
sentative sample of 157 (31%) subjects, 2 early morning first-voided
spot urine collections were available, and the presence of normoal-
buminuria for these subjects was therefore based on the mean
albumin-to-creatinine ratio of the 2 urine collections. Subjects were
classified as having normoalbuminuria when they had a urinary
albumin concentration below the assay threshold (6.2 mg/L, n5321)
or a (mean) albumin-to-creatinine ratio #2.0 mg/mmol (n5188).
(An overnight albumin-to-creatinine ratio .2.0 mg/mmol has a high
sensitivity to detect an albumin excretion rate .30 mg/min.23) The
presence of leukocytes and nitrite was tested by dipstick.
We obtained data on blood pressure, weight, height, waist and hip
circumference, fasting and 2-hour postload glucose, glycated hemo-
globin, and serum fasting specific insulin, creatinine, homocysteine,
urea nitrogen, albumin, total cholesterol, HDL cholesterol, and
triglyceride levels.16,21,22 Hypertension was defined as diastolic
pressure $95 mm Hg, systolic pressure $160 mm Hg, and/or the use
of antihypertensive drugs.21 Insulin resistance was calculated by
using the homeostasis model assessment formula (fasting
insulin3fasting glucose/22.424). The glomerular filtration rate (GFR)
was estimated in 2 ways: (1) from the Cockcroft-Gault formula25 for
creatinine clearance (n5340, 100%) and (2) from the formula
proposed by the Modification of Diet in Renal Disease Study Group
(MDRD formula; n5330, 97.0%): GFR51703(serum creatinine
level [mg/dL])20.7263(age)20.1763(0.762 if patients is female)3(1.180
if patient is black)3(serum urea nitrogen level [mg/
dL])20.1703(serum albumin level [g/dL])0.318.26 Information about
smoking habits and dietary protein intake was obtained with stan-
dardized questionnaires.21 Current smoking was defined as currently
smoking cigarettes and/or cigars. We obtained an ankle-brachial
blood pressure index and a resting ECG, as previously described.21,22
The cardiovascular and cerebrovascular history was obtained by
means of the self-administered Rose questionnaire (n5340, 100%).21
Subjects were classified as having cardiovascular disease when they
had an ankle-brachial pressure index ,0.9 in either leg, when they
had undergone a peripheral arterial bypass or amputation, when they
had an ECG with a Minnesota code 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3,
or 7.1, when they had undergone coronary bypass surgery or
angioplasty, and/or when they had self-reported myocardial infarc-
tion and/or cerebrovascular disease (n5338, 99.4%). Retinopathy
was assessed by ophthalmoscopy (n5337, 99.1%) and/or fundus
photography (n5253, 74.4%). (Fundus photographs of 87 [25.6%]
subjects were lost. Loss was random with regard to age, sex,
hypertension, and glucose tolerance categories [data not shown].)
Both eyes were dilated, whereupon indirect and direct ophthalmos-
copy was carried out by 1 of 2 ophthalmologists. Thereafter, 2 black
and white photographs were taken of each eye, centered on the
macular area and the optic disc. Both ophthalmoscopic and fundus
photographic findings were independently graded by 2 ophthalmol-
ogists according to the modified Airlie House Classification.27 In
case of disagreement, the independent judgment of a third ophthal-
mologist was taken to be decisive. Retinopathy was defined as the
presence of $1 hemorrhages, microaneurysms, soft and hard exu-
dates, areas of neovascularization, and/or laser coagulation scars in at
least 1 eye (n5336, 98.8%).
Procedures at the Follow-Up Examination
All participants were asked to hand in an overnight first-voided and
an untimed spot urine sample. In a representative sample (n5161),
subjects were asked to hand in a second set of urine samples within
4 weeks. Of all 340 participants, 4 collected no urine samples, 18
collected 1 sample, 168 collected 2 samples, 10 collected 3 samples,
and 140 collected 4 samples. The urinary albumin-to-creatinine
ratios were determined, and in case of .1 urine collection per
participant, the mean albumin-to-creatinine ratio was calculated.
Urinary albumin assessments below the threshold (2.0 mg/L) were
set at 1.5 mg/L (n551 urine samples among 38 subjects, 8% of all
Figure 1. Study outline.
Jager et al Homocysteine: A Risk Factor for (Micro)albuminuria 75
urine samples). Subjects were classified as having normoalbuminuria
when the mean albumin-to-creatinine ratio was #2.0 mg/mmol and
as having (micro)albuminuria when the mean albumin-to-creatinine
ratio was .2.0 mg/mmol. (An overnight albumin-to-creatinine ratio
.2.0 mg/mmol has a high sensitivity to detect an albumin excretion
rate .30 mg/min.23) Subjects who used an ACE inhibitor (n520)
were excluded from further analyses (Figure 1). The presence of
leukocytes and nitrite was tested by dipstick.
Assays
Urinary albumin was measured by rate nephelometry (Array Protein
System, Beckman) with intra-assay and interassay coefficients of
variation of #5% and #8%, respectively (assay threshold was 6.2
mg/L at baseline and 2.0 mg/L at follow-up examination). Urinary
and serum creatinine was measured by a modified Jaffe’s test. Serum
homocysteine concentrations were determined by high-performance
liquid chromatography with fluorescence detection.16 Serum levels
of urea nitrogen concentration were determined in samples stored at
270°C by a kinetic UV assay from Roche Diagnostics. Serum
albumin levels were assessed by use of the bromcresol purple
method. Levels of fasting and 2-hour postload venous plasma
glucose, glycated hemoglobin, serum-specific fasting insulin, tri-
glycerides, and total and HDL cholesterol were determined as
previously described in detail.21,22
Statistical Analyses
All analyses were performed with SPSS 7.5 for Windows 95.
Differences between 2 groups in continuous variables that had a
normal distribution were tested by Student t test; for continuous
variables that had a skewed distribution, Mann-Whitney tests were
used; and for the percentage of subjects with versus without the
presence of dichotomous variables, the x2 test was used. To elucidate
the associations of potential determinants with the development of
(micro)albuminuria, logistic regression analyses were performed
with the presence of (micro)albuminuria at follow-up as dependent
variables and with potential determinants at baseline as independent
variables. The Wald test was used to test significance. (Performing
the analyses according to the log likelihood test gave similar results.)
All ORs for developing (micro)albuminuria were adjusted for the
original stratification variables: age, sex, and glucose tolerance status
(ie, impaired glucose tolerance and NIDDM). Potential determinants
measured on a continuous scale were used as such in the regression
models, except for glycated hemoglobin, HDL cholesterol, body
mass index, and protein intake, because the association of these
variables with incident (micro)albuminuria was nonlinear. There-
fore, a high glycated hemoglobin level was defined as a level
.6.5%; a low HDL cholesterol level was defined as a level
,0.9 mmol/L22; a high body mass index was defined as values .27
kg/m2 for men and .26 kg/m2 for women22; and a high protein
intake was defined as an intake .1.25 g/kg per day. Insulin
resistance and fasting insulin and triglyceride levels were logarith-
mically transformed because of a better fit of the regression model.
We evaluated a possible dose-response relation of homocysteine by
calculating ORs for developing (micro)albuminuria for several
ranges of homocysteine concentrations (9.1 to 14.0, 14.1 to 19.0, and
.19.0 mmol/L) with homocysteine levels ,9.1 mmol/L as reference.
By using this procedure, we evaded assumptions about linearity.16,28
To assess whether determinants were independently associated with
development of (micro)albuminuria, regression analyses were pri-
marily adjusted for all variables that were statistically significant in
the initial analyses and secondarily for other potential variables of
interest. All these variables were entered simultaneously into the
regression models. Two-sided values of P,0.05 were considered
statistically significant.
Results
The mean duration of follow-up was 6.1 years (SD 0.7 years,
range 4.4 to 7.7 years). The cumulative incidence of (mi-
cro)albuminuria at 6.1 years of follow-up was 14.0% (95% CI
9.7 to 19.3) among nondiabetic subjects and 22.7% (95% CI
12.9 to 32.5) among NIDDM patients. The cumulative
incidence of (micro)albuminuria increased with categories of
increasing homocysteine levels (Figure 2).
Compared with subjects who participated in the follow-up
examination, subjects who died during the follow-up period
were older, more insulin resistant, more obese, and more
often smokers, and they more often had NIDDM, hyperten-
sion, cardiovascular disease, higher levels of homocysteine
and triglycerides, and a lower protein intake at baseline (data
not shown). The nonresponders (Figure 1) were not materi-
ally different from those who did participate in the following
examination with regard to the variables shown in Table 1,
except that nonresponders were older (65 versus 63 years)
and had higher levels of homocysteine (13.1 versus 11.8
mmol/L).
Compared with subjects who did not develop (micro)albu-
minuria, subjects who developed (micro)albuminuria were
significantly older, more insulin resistant, and more obese;
they had higher blood pressures and higher fasting insulin and
homocysteine levels; and they more often had hypertension,
cardiovascular disease, and retinopathy at baseline (Table 1).
Age-adjusted, sex-adjusted, and glucose tolerance–adjusted
logistic regression analyses showed the development of
(micro)albuminuria to be significantly associated with age,
male sex, fasting insulin levels, insulin resistance, systolic
and diastolic blood pressure, the presence of hypertension,
body mass index, homocysteine levels, and the presence of
cardiovascular disease (Table 2). Analyses performed in
nondiabetic and diabetic subjects separately gave similar
results, except for the association between the development of
(micro)albuminuria on the one hand and glycated hemoglobin
and homocysteine levels on the other, which could be
estimated only among nondiabetic subjects (Table 2), the
latter because there was only 1 diabetic subject with homo-
cysteine levels .19.0 mmol/L.
To further investigate the association between develop-
ment of (micro)albuminuria and potential determinants, mul-
tiple regression analyses were performed with all variables
significantly associated with the development of (micro)al-
buminuria (Table 2), as well as the stratification variables, as
independent variables. These adjustments did not materially
affect the results, except for the association between the
development of (micro)albuminuria and fasting insulin levels,
which was no longer statistically significant (Table 3).
Figure 2. Cumulative incidence of (micro)albuminuria per cate-
gory of homocysteine level. *Estimated by age-adjusted, sex-
adjusted, and glucose tolerance–adjusted logistic regression
analyses.
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Further adjustment for creatinine clearance did not materially
change the association between homocysteine level and the
development of (micro)albuminuria (eg, among all subjects,
the ORs were 1.4 [95% CI 0.5 to 3.8], 1.7 [95% CI 0.5 to 5.5],
and 7.6 [95% CI 1.5 to 39.3] for homocysteine levels of 9.1
to 14.0, 14.1 to 19.0, and .19.0 mmol/L compared with
homocysteine levels ,9.1 mmol/L, respectively). Substitut-
ing GFR estimated from the MDRD formula for creatinine
clearance again did not materially change the association
between homocysteine level and the development of (mi-
cro)albuminuria (eg, among all subjects, the ORs were 1.4
[95% CI 0.5 to 3.9], 1.7 [95% CI 0.5 to 5.5], and 8.4 [95% CI
1.6 to 44.8] for homocysteine levels of 9.1 to 14.0, 14.1 to
19.0, and .19.0 mmol/L compared with homocysteine levels
of ,9.1 mmol/L, respectively). Additional adjustment for
retinopathy and current smoking also did not materially
change the results (data not shown). Substituting insulin
resistance for fasting insulin levels or systolic blood pressure
or hypertension for diastolic blood pressure again did not
materially change the results (data not shown). Changing the
cutoff levels of categories of homocysteine levels (,10.1
[reference category], 10.1 to 14.0, 14.1 to 18.0, and .18.0
mmol/L) somewhat decreased the ORs for developing (mi-
cro)albuminuria (eg, among all subjects, 1.0 [reference cate-
gory], 1.0 [95% CI 0.4 to 2.2], 1.3 [95% CI 0.5 to 3.5], and
4.8 [95% CI 1.3 to 18.0], respectively, after adjusting for
the determinants shown in Table 3). Substituting homocys-
teine levels as continuous variables for categories of homo-
cysteine levels showed that a 5-mmol/L increase of the
homocysteine level was associated with a 1.4 (95% CI 0.97 to
2.0) increased risk of developing (micro)albuminuria after
adjusting for the determinants shown in Table 3.
Among all subjects, the ORs of developing (micro)albu-
minuria after adjustment for the determinants shown in Table
3 were 2.0 (95% CI 0.7 to 5.6) for total protein intake (.1.25
g/kg per day versus #1.25 g/kg per day) and 2.7 (95% CI 1.0
to 7.3) for retinopathy (yes versus no).
Additional Analyses
The following additional analyses did not materially affect
our results: analyses with (micro)albuminuria defined as an
albumin-to-creatinine ratio .3.0 instead of .2.0 mg/mmol,
analyses with (micro) albuminuria defined on the basis of
first-voided overnight urine or untimed spot urine samples
only, analyses with (micro)albuminuria defined on the basis
of the median albumin-to-creatinine ratio, analyses after
exclusion of subjects who developed macroalbuminuria (as
defined by an albumin-to-creatinine ratio .30 mg/mmol,
n53), analyses after exclusion of urine samples with a
positive dipstick test for leukocytes and/or nitrite at baseline
(n549) and/or at follow-up (n547) measurement, and
(among nondiabetic subjects) analyses that excluded subjects
with impaired glucose tolerance (n586, data not shown).
Discussion
In the present prospective study, we showed that hyperhomo-
cysteinemia is an independent determinant of the develop-
ment of (micro)albuminuria among nondiabetic subjects,
even after adjustment for 2 different estimates of the glomer-
ular filtration rate.24,25 We could neither confirm nor reject an
association between homocysteine and the development of
(micro)albuminuria among NIDDM subjects. These data are
in line with previous cross-sectional findings16–18 and support
the hypothesis that homocysteine may play a pathophysio-
logical role in the development of (micro)albuminuria.
This is the first study showing that an increased homocys-
teine level precedes the development of (micro)albuminuria.
This is an important step toward establishing high homocys-
teine levels as a causal risk factor for (micro)albuminuria, as
previously suggested by cross-sectional studies.16–18 We
found a possible threshold of homocysteine level above
which the risk of (micro)albuminuria increased at ’19
mmol/L, which is similar to the threshold of 18 mmol/L found
TABLE 1. Baseline Characteristics According to Albuminuria
Status at Follow-Up
Persistent
Normoalbuminuria
(n5266)
Development of
(Micro)albuminuria
(n550)
Male/female, n/n 128/138 30/20
Age, y 6267 6667¶
Fasting glucose, mmol/L 6.261.8 6.661.9
Glycated hemoglobin, % 5.661.0 5.761.0
Fasting insulin,* pmol/L 79 (60–107) 103 (75–138)¶
Insulin resistance
(dimensionless)*†
20.4 (14.5–30.7) 27.3 (19.5–43.1)¶
Impaired glucose tolerance, % 26 32
NIDDM, % 19 30
Diastolic blood pressure, mm Hg 8169 8669¶
Systolic blood pressure, mm Hg 133616 145618¶
Hypertension, % 23 56¶
Waist-to-hip ratio (men) 0.9660.06 0.9760.07
Waist-to-hip ratio (women) 0.8660.08 0.9060.07¶
Body mass index, kg/m2 26.463.4 27.863.7¶
Total cholesterol, mmol/L 6.661.1 6.561.4
HDL cholesterol, mmol/L 1.360.4 1.260.3
Triglycerides,* mmol/L 1.5 (1.0–2.1) 1.5 (1.2–2.3)
Homocysteine, mmol/L 11.664.3 13.064.0¶
Total protein intake,
g z kg21 z d21
1.060.3 1.060.3
Animal protein intake,
g z kg21 z d21
0.760.2 0.760.2
Cardiovascular disease,‡ % 14 34¶
Retinopathy, % 8 18¶
Current smoking, % 28 20
Creatinine clearance,§ mL/min 80617 78618
Range 42–150 42–120
GFR,\ mL z min21 z 1.73 m22 70611 68612
Range 44–102 43–100
Data are means6SD unless otherwise indicated.
*Median (25–75th percentiles).
†Calculated according to homeostasis model assessment formula (fasting
insulin3fasting glucose/22.4).23
‡Ankle-brachial pressure index ,0.90 and/or peripheral bypass operation,
amputation and/or Minnosota code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1 on ECG,
coronary bypass operation or angioplasty, and/or self-reported myocardial
infarction or cerebrovascular disease.
§Calculated by Cockcroft-Gault formula.24
\Calculated according to MDRD formula.25
¶P,0.05 vs persistent normoalbuminuria.
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in our previous cross-sectional study.16 Clearly, the present
study is too small to establish with certainty the existence and
the exact level of such a threshold.
The pathophysiological pathway linking homocysteine
level and risk of (micro)albuminuria is unknown. Some
evidence suggests that hyperhomocysteinemia enhances oxi-
dative stress, which could induce endothelial and mesangial
cell dysfunction.29 Intact renal endothelial and mesangial cell
function is important for regulating intraglomerular pressure
and glomerular charge and size selectivity. Dysfunction of
these cells may increase intraglomerular pressure and/or
decrease glomerular charge and size selectivity and thus
cause microalbuminuria. Alternatively, hyperhomocysteine-
mia and (micro)albuminuria could be associated through a
common pathophysiological pathway; eg, inadequate vitamin
B6, B12, and/or folate status could be the common antecedent
leading to hyperhomocysteinemia on the one hand and to the
development of (micro)albuminuria on the other. However,
there is no evidence that inadequate B-vitamin status can
directly cause (micro)albuminuria. Finally, hyperhomocys-
teinemia could be indirectly related to (micro)albuminuria; ie,
hyperhomocysteinemia may influence another factor, such as
TABLE 2. Age-Adjusted, Sex-Adjusted, and Glucose Tolerance–Adjusted ORs for Developing
(Micro)albuminuria of Potential Determinants
All Subjects
(n5316), OR
(95% CI)*
Nondiabetic
Subjects
(n5250), OR
(95% CI)*
Diabetic Subjects
(n566), OR
(95% CI)*
Age (per 5-year increase) 1.5 (1.2–1.9) 1.4 (1.1–1.8) 1.9 (1.1–3.2)
Male (vs female) 2.0 (1.0–3.7) 1.6 (0.8–3.3) 3.6 (0.98–13.2)
Fasting insulin (per 10% increase) 1.1 (1.0–1.2) 1.1 (0.99–1.2) 1.2 (0.98–1.4)
Insulin resistance (per 10% increase)‡ 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.1 (0.96–1.3)
Glycated hemoglobin (. vs #6.0%) 1.4 (0.6–3.2) 1.6 (0.5–5.1) 1.0 (0.3–3.8)
Impaired glucose tolerance (vs NGT) 1.5 (0.7–3.2) 1.6 (0.7–3.3) z z z
NIDDM (vs NGT) 2.1 (0.96–4.5) z z z z z z
DBP (per 10 mm Hg increase) 1.9 (1.4–2.8) 2.0 (1.3–2.9) 2.3 (1.0–5.3)
SBP (per 10 mm Hg increase) 1.4 (1.1–1.7) 1.5 (1.2–1.8) 1.2 (0.8–1.8)
Hypertension (yes vs no) 3.8 (2.0–7.5) 3.8 (1.7–8.2) 4.6 (1.1–18.7)
Waist-to-hip ratio (per 0.01 increase) 1.0 (0.98–1.1) 1.0 (0.99–1.1) 1.0 (0.9–1.1)
Body mass index (yes vs no)§ 3.1 (1.5–6.3) 2.6 (1.2–5.7) 5.9 (1.0–33.7)
Total cholesterol (per 1-mmol/L increase) 1.0 (0.8–1.3) 1.1 (0.8–1.6) 0.8 (0.4–1.4)
HDL cholesterol (# vs .0.9 mmol/L) 1.4 (0.5–3.7) 2.4 (0.7–7.7) 0.4 (0.1–2.8)
Triglycerides (per 10% increase) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.0 (0.9–1.1)
Homocysteine
9.1–14.0 vs ,9.1 mmol/L† 1.2 (0.5–3.0) 1.2 (0.4–3.6) 1.0 (0.2–6.4)
14.1–19.0 vs ,9.1 mmol/L† 1.8 (0.6–5.3) 1.4 (0.4–5.0) 3.6 (0.5–28.4)
.19.0 vs ,9.1 mmol/L† 5.1 (1.1–23.0)\ 5.6 (1.1–27.6)\ z z z¶
Homocysteine (per 5-mmol/L increase) 1.3 (0.9–1.8) 1.2 (0.9–1.8) 1.6 (0.6–4.5)
Total protein intake (. vs #1.25
g z kg21 z d21)
1.4 (0.6–3.3) 1.7 (0.6–4.7) 0.8 (0.1–4.6)
Cardiovascular disease (yes vs no)‡ 2.2 (1.1–4.3) 2.4 (1.1–5.3) 1.6 (0.4–6.2)
Retinopathy (yes vs no) 2.3 (0.96–5.7) 2.2 (0.8–5.8) 3.7 (0.4–36.2)
Creatinine clearance
51–80 vs .80 mL/min‡ 1.1 (0.5–2.8) 0.8 (0.3–1.9) 2.01 (0.46–8.83)
,51 vs .80 mL/min‡ 2.43 (0.55–10.78) 1.60 (0.31–8.30) z z z#
GFR (per 10-mL z min21 z 1.73 m22
decrease)‡
1.23 (0.90–1.67) 0.95 (0.73–1.49) 1.79 (0.94–3.45)
NGT indicates normal glucose tolerance; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
*OR and 95% CI were performed by logistic regression analyses with development of (micro)albuminuria as
dependent variable.
†Among nondiabetic subjects, the numbers of subjects with microalbuminuria per increasing category of
homocysteine levels were 5 of 56, 18 of 137, 8 of 47, and 4 of 10, respectively. Among diabetic subjects, the numbers
of subjects with microalbuminuria per increasing category of homocysteine levels were 2 of 17, 7 of 37, 6 of 11, and
0 of 1, respectively.
‡Described in legend to Table 1.
§.27 vs #27 kg/m2 for men and .26 vs #26 kg/m2 for women.
\P,0.05 for trend of the homocysteine categories.
¶One subject with homocysteine levels .19.0 mmol/L.
#Only 3 subjects with creatinine clearance ,51 mL/min.
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blood pressure, which directly causes the development of
(micro)albuminuria. We found no evidence that this was the
case. Nevertheless, we clearly cannot rule out these possibil-
ities, and experimental work will be necessary to establish
whether the association between homocysteine and microal-
buminuria is causal.
Was confounding by variables other than vitamin status
sufficiently excluded in our analyses? We adjusted for im-
portant variables known to affect homocysteine levels, such
as sex, impaired renal function, and smoking habits, so it is
unlikely that these factors confounded our results.
Follow-up was not complete (Figure 1), and it is important
to consider whether this may have biased the association
between homocysteine level and risk of incident (micro)al-
buminuria. First, 50 of the 509 subjects investigated at
baseline died during follow-up. We have previously shown in
this population that mortality risk is related to having
NIDDM,22 (micro)albuminuria,22 and high homocysteine lev-
els, especially in the presence of NIDDM,30 and that high
homocysteine levels and microalbuminuria are associated in
cross-sectional analyses.16 Indeed, subjects who died had
higher homocysteine levels at baseline than did those who
survived. Taken together, these data suggest that compared
with subjects who survived, subjects who died may have been
at increased risk of developing (micro)albuminuria; this
would result in an underestimation of the association between
high homocysteine levels and the risk of (micro)albuminuria,
in particular among diabetic subjects. Second, 119 nonre-
sponders and 20 subjects who used ACE inhibitors were
excluded from the analyses. Given their clinical profile, these
subjects may have been at increased risk of developing
(micro)albuminuria compared with the participants, but again
it is not clear why this should have led to an overestimation
of the relation between homocysteine levels and the risk of
(micro)albuminuria. Therefore, we conclude that, if anything,
the incomplete follow-up may have resulted in an underesti-
mation of the association between high homocysteine levels
and incident (micro)albuminuria.
In the present study, the cumulative incidence of (micro)al-
buminuria after 6.1 years of follow-up was 14.0% among
nondiabetic subjects and 22.7% among NIDDM patients,
which is in agreement with previous reports.4,7,10,11 Risk of
developing (micro)albuminuria was associated not only with
high homocysteine levels but also with age, blood pressure,
body mass index, and the presence of cardiovascular disease
and retinopathy. The association with age is in accordance
with other studies10 but is poorly understood mechanistically.
Hypertension may increase intraglomerular pressure31 and
thus promote albumin leakage,5,8,9 although prospective stud-
ies do not show consistent results.6,7,10,11 Obesity may in-
crease the risk of microalbuminuria by altering intraglomer-
ular hemodynamics.14 However, the association between
obesity and microalbuminuria again is not consistently
observed.5,9,10
The link between retinopathy and (micro)albuminuria ob-
served in the present and in previous prospective8,10 studies
can probably be understood by considering that both reflect
microangiopathy and thus share certain pathogenetic mecha-
nisms, such as endothelial dysfunction. Endothelial dysfunc-
tion may also explain why the presence of cardiovascular
disease confers an increased risk of incident microalbumin-
uria11 as well as the converse.32
TABLE 3. Multiple Logistic Regression Analyses With Development of
(Micro)albuminuria as Dependent Variable
All Subjects
(n5316), OR
(95% CI)*
Nondiabetic
Subjects
(n5250), OR
(95% CI)*
Diabetic Subjects
(n566), OR
(95% CI)*
Age (per 5-year increase) 1.5 (1.1–1.9) 1.3 (0.97–1.8) 2.5 (1.2–5.2)
Male (vs female) 1.9 (0.9–3.8) 1.5 (0.6–3.4) 4.4 (0.9–21.7)
Fasting insulin (per 10% increase)† 1.0 (0.96–1.1) 1.0 (0.95–1.1) 1.1 (0.9–1.3)
Impaired glucose tolerance (vs NGT) 1.1 (0.5–2.5) 1.1 (0.5–2.5) z z z
NIDDM (yes vs no) 1.4 (0.6–3.3) z z z z z z
DBP (per 10 mm Hg increase)† 1.9 (1.3–2.8) 1.9 (1.2–3.0) 3.1 (1.0–9.4)
Body mass index (yes vs no)‡ 2.6 (1.2–5.8) 2.3 (0.9–5.6) 2.8 (0.4–20.0)
Cardiovascular disease (yes vs no)§ 2.4 (1.2–5.0) 2.7 (1.1–6.4) 2.3 (0.4–12.5)
Homocysteine
9.1–14.0 vs ,9.1 mmol/L 1.4 (0.5–3.8) 1.7 (0.5–5.3) 0.6 (0.1–5.5)
14.1–19.0 vs ,9.1 mmol/L 1.9 (0.6–5.7) 1.6 (0.4–6.0) 1.9 (0.2–19.0)
.19.0 vs ,9.1 mmol/L 8.5 (1.7–42.6)\ 12.2 (2.1–69.8)\ z z z‡
Variables included in this analysis were those that were significantly (P,0.05) associated with the
development of microalbuminuria in initial analyses among all subjects (Table 2, first column). The
variables “impaired glucose tolerance” and “NIDDM” were also included in the model, because they
were stratification variables.
*OR (95% CI) of developing microalbuminuria obtained by logistic regression analyses.
†Substituting insulin resistance for fasting insulin levels or SBP or hypertension for DBP did not
materially change the result.
‡Described in Table 2.
§Described in Table 1.
\P,0.05 for trend of the homocysteine categories.
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Hyperglycemia can increase intraglomerular pressure and
induce the loss of negative charges on the glomerular base-
ment membrane, resulting in enhanced renal albumin leak-
age.31,33 Moreover, poor glycemic control has been shown to
precede the development of microalbuminuria in diabetic
subjects.6,8,10,11 Nevertheless, in the present study, we could
not demonstrate glycemic control or the presence of NIDDM
to be associated with incident (micro)albuminuria. The num-
ber of NIDDM subjects in the present study might have been
too small; ie, there was a lack of power. Alternatively,
selective mortality or selective improvement of glycemic
control during follow-up among NIDDM subjects with a
high, compared with those with a low, glycated hemoglobin
level might explain the present findings.
Microalbuminuria has been proposed to be part of the
insulin resistance syndrome,12,13 but not all studies con-
cur.20,34,35 Previous prospective studies4 have not demon-
strated a high insulin level or insulin resistance to be
associated with an increased risk of developing microalbu-
minuria, which is in accordance with the present data.
Protein intake was not clearly associated with the risk of
incident (micro)albuminuria, which contrasts somewhat with
our previous cross-sectional finding.16 We assessed protein
intake at baseline only. This may have been a poor estimate
of protein intake during follow-up, inasmuch as dietary
changes are likely, which would dilute any “true” association
between protein intake and the risk of incident
(micro)albuminuria.
The main limitation of the present study is the small
number of subjects, resulting in risk estimates with large CIs,
ie, substantial uncertainty. On the other hand, the main
findings seem quite robust, inasmuch as adjustment for
potential determinants did not materially change these
findings.
In conclusion, we have shown that a high homocysteine
level is independently associated with an increased risk of
developing (micro)albuminuria. This finding supports the
hypothesis that hyperhomocysteinemia may be a causal
determinant of (micro)albuminuria, although further mecha-
nistic work is needed to prove this hypothesis. Nevertheless,
our findings could be of clinical relevance, because increased
levels of homocysteine can be effectively treated with folic
acid, vitamin B6, and/or vitamin B12.36,37
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